Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib in recurrent or persistent uterine leiomyosarcoma
NCT02378142Phase 2Withdrawn
- Sponsor
- GOG Foundation
- Start
- Mar 2015
- Primary completion
- Jan 2018
01
Overview
A Phase 2 trial of pazopanib in uterine leiomyosarcoma (uLMS), sponsored by GOG Foundation. Planned start Mar 2015; status: withdrawn.
02
Drugs
pazopanib
03
Conditions
uterine leiomyosarcoma (uLMS)
Beyond the preview
Go deeper on NCT02378142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378142.